Diamir Biosciences CORP S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
DiamiR Biosciences updates its S-1 registration statement to address SEC comments and reflect financials for the quarter ended August 31, 2024, as it prepares for its initial public offering.
DiamiR Biosciences Corp. amends its S-1 registration statement, aiming for a NASDAQ listing to advance its molecular diagnostics for neurodegenerative diseases.
DiamiR Biosciences Corp. amends its S-1 registration statement to revise disclosures in response to SEC comments for its upcoming IPO.
DiamiR Biosciences Corp. files an S-1 registration statement for an initial public offering to fund the development and commercialization of blood-based diagnostic tests for neurodegenerative diseases.